Form 4 for GH Guardant Health, Inc.
Accepted 2026-08-13 19:21:04 ET · period of report 2026-08-12 · accession 0001652956-26-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-13 19:21 | 2026-08-12 | GH | Monroe Terilyn J. | CHRO | M - OptEx | $22.70 | +46.3K | 69.3K | +201% | +$1.05M |
| DM | 2026-08-13 19:21 | 2026-08-12 | GH | Monroe Terilyn J. | CHRO | S - Sale+OE | $165.12 | -46.3K | 23.0K | -67% | -$7.65M |
| DM | 2026-08-13 19:21 | 2026-08-12 | GH | Monroe Terilyn J. | CHRO | M - OptEx | $0.00 | -46.3K | 18.6K | -71% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-12 | M | A | 32,288 | $20.14 | 55,267 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-12 | M | A | 14,012 | $28.61 | 69,279 | D | — | — | |
| 3 | Common | Common Stock | 2026-08-12 | S | D | 3,704 | $163.41 | 65,575 | D | — | — | (F1) Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $162.80 to $163.78. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Common | Common Stock | 2026-08-12 | S | D | 9,934 | $164.27 | 55,641 | D | — | — | (F2) Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.81 to $164.805. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Common | Common Stock | 2026-08-12 | S | D | 19,014 | $165.16 | 36,627 | D | — | — | (F3) Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.825 to $165.82. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 6 | Common | Common Stock | 2026-08-12 | S | D | 13,248 | $166.11 | 23,379 | D | — | — | (F4) Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.85 to $166.825. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 7 | Common | Common Stock | 2026-08-12 | S | D | 400 | $167.92 | 22,979 | D | — | — | (F5) Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.695 to $168.02. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 8 | Derivative | Stock Option (Right to Buy) | 2026-08-12 | M | D | 32,288 | $0.00 | 10,916 | D | $20.14 · — to 2034-02-26 | 32,288 Common Stock | (F6) This represents a stock option award granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 2, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-08-12 | M | D | 14,012 | $0.00 | 18,615 | D | $28.61 · — to 2034-11-08 | 14,012 Common Stock | (F7) This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. |